Based on this rationale, we focused on the clinicopathological characteristics according to critical mutations by describing the mutational landscape in a broad cohort of GIST patients and investigated the predictive role of the type and codon location of the KIT exon 11 mutations in metastatic GIST patients treated with first-line imatinib. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.